Rainer Kramer
Corporate Officer/Principal chez IMMATICS N.V.
Fortune : 3 M $ au 31/03/2024
Profil
Rainer Kramer is currently the Director at Immatics US, Inc. He also holds positions as the Chief Business Officer at Immatics Biotechnologies GmbH and Immatics NV.
Additionally, he is a Member-Supervisory Board at iOmx Therapeutics AG.
Previously, he held positions as the Principal at Amgen, Inc., Head-Business Development at MorphoSys AG, Vice President-Business Development at Shire Orphan Therapies GmbH, and Chief Business Officer at Signature Diagnostics AG.
Dr. Kramer received his undergraduate degree from the University of Regensburg and his doctorate from the Max Planck Institute of Neurobiology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMATICS N.V.
0,31% | 31/01/2024 | 319 575 ( 0,31% ) | 3 M $ | 31/03/2024 |
Postes actifs de Rainer Kramer
| Sociétés | Poste | Début |
|---|---|---|
| IMMATICS N.V. | Corporate Officer/Principal | 01/01/2012 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Corporate Officer/Principal | 01/04/2012 |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Director/Board Member | - |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Director/Board Member | 20/07/2022 |
Anciens postes connus de Rainer Kramer
| Sociétés | Poste | Fin |
|---|---|---|
Signature Diagnostics AG
 Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Signature Diagnostics AG operates as a molecular diagnostics company. It discovers, validates and develops novel diagnostic products that predict outcome and drug response in patients with colorectal cancer, non-small cell lung cancer and ovarian cancer. The company was founded by André Rosenthal in 2004 and is headquartered in Potsdam, Germany. | Corporate Officer/Principal | 01/05/2012 |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Corporate Officer/Principal | 01/08/2009 |
| MORPHOSYS AG | Corporate Officer/Principal | 01/01/2003 |
| AMGEN INC. | Corporate Officer/Principal | - |
Formation de Rainer Kramer
| University of Regensburg | Undergraduate Degree |
| Max Planck Institute of Neurobiology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| MORPHOSYS AG | Health Technology |
| IMMATICS N.V. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Health Technology |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Signature Diagnostics AG
Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Signature Diagnostics AG operates as a molecular diagnostics company. It discovers, validates and develops novel diagnostic products that predict outcome and drug response in patients with colorectal cancer, non-small cell lung cancer and ovarian cancer. The company was founded by André Rosenthal in 2004 and is headquartered in Potsdam, Germany. | Health Technology |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Health Technology |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Health Technology |
